Literature DB >> 34613807

Design of the Recombinant Influenza Neuraminidase Antigen Is Crucial for Its Biochemical Properties and Protective Efficacy.

Jin Gao1, Laura Klenow1, Lisa Parsons2, Tahir Malik1, Je-Nie Phue3, Zhizeng Gao4, Stephen G Withers4, John Cipollo2, Robert Daniels1, Hongquan Wan1.   

Abstract

Supplementing influenza vaccines with recombinant neuraminidase (rNA) antigens remains a promising approach for improving suboptimal vaccine efficacy. However, correlations among rNA designs, properties, and protection have not been systematically investigated. Here, we performed a comparative analysis of several rNAs produced by the baculovirus/insect cell system. The rNAs were designed with different tetramerization motifs and NA domains from a recent H1N1 vaccine strain (A/Brisbane/02/2018) and compared for enzymatic properties, antigenicity, stability, and protection in mice. We found that the enzymatic properties differ between rNAs containing the NA head domain versus the full ectodomain, the formation of higher-order rNA oligomers is tetramerization domain dependent, whereas the protective efficacy is more contingent on the combination of the tetramerization and NA domains. Following single-dose immunizations, an rNA possessing the full ectodomain and the tetramerization motif from the human vasodilator-stimulated phosphoprotein provided much better protection than an rNA with ∼10-fold more enzymatically active molecules that is comprised of the head domain and the same tetramerization motif. In contrast, these two rNA designs provided comparable protection when the tetramerization motif from the tetrabrachion protein was used instead. These findings demonstrate that individual rNAs should be thoroughly evaluated for vaccine development, as the heterologous domain combination can result in rNAs with similar key attributes that vastly differ in protection. IMPORTANCE For several decades, it has been proposed that influenza vaccines could be supplemented with recombinant neuraminidase (rNA) to improve efficacy. However, some key questions for manufacturing stable and immunogenic rNAs remain to be answered. We show here that the tetramerization motifs and NA domains included in the rNA construct design can have a profound impact on the biochemical, immunogenic, and protective properties. We also show that the single-dose immunization regimen is more informative for assessing the rNA immune response and protective efficacy, which is surprisingly more dependent on the specific combination of NA and tetramerization domains than common attributes for evaluating NA. Our findings may help to optimize the design of rNAs that can be used to improve or develop influenza vaccines.

Entities:  

Keywords:  immune response; influenza vaccine improvement; protective efficacy; recombinant antigen optimization; recombinant neuraminidase

Mesh:

Substances:

Year:  2021        PMID: 34613807      PMCID: PMC8610580          DOI: 10.1128/JVI.01160-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Ultrasensitive Fluorogenic Reagents for Neuraminidase Titration.

Authors:  Zhizeng Gao; Masahiro Niikura; Stephen G Withers
Journal:  Angew Chem Int Ed Engl       Date:  2017-02-13       Impact factor: 15.336

2.  Assembly of subtype 1 influenza neuraminidase is driven by both the transmembrane and head domains.

Authors:  Diogo V da Silva; Johan Nordholm; Ursula Madjo; Annika Pfeiffer; Robert Daniels
Journal:  J Biol Chem       Date:  2012-11-13       Impact factor: 5.157

3.  Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.

Authors:  Ian C Brett; Bert E Johansson
Journal:  Virology       Date:  2005-09-01       Impact factor: 3.616

4.  Identification of Residues That Affect Oligomerization and/or Enzymatic Activity of Influenza Virus H5N1 Neuraminidase Proteins.

Authors:  Meiling Dai; Hongbo Guo; Jos C F M Dortmans; Jojanneke Dekkers; Johan Nordholm; Robert Daniels; Frank J M van Kuppeveld; Erik de Vries; Cornelis A M de Haan
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

5.  Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response.

Authors:  B E Johansson; J T Matthews; E D Kilbourne
Journal:  Vaccine       Date:  1998 May-Jun       Impact factor: 3.641

6.  Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice.

Authors:  J L Schulman; M Khakpour; E D Kilbourne
Journal:  J Virol       Date:  1968-08       Impact factor: 5.103

7.  Randomized comparison of the safety of Flublok(®) versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥ 50 years of age.

Authors:  Ruvim Izikson; David J Leffell; S Allan Bock; Peter A Patriarca; Penny Post; Lisa M Dunkle; Manon M J Cox
Journal:  Vaccine       Date:  2015-11-01       Impact factor: 3.641

8.  Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system.

Authors:  Irina Margine; Peter Palese; Florian Krammer
Journal:  J Vis Exp       Date:  2013-11-06       Impact factor: 1.355

9.  Immunogenicity of influenza A virus N2 neuraminidase produced in insect larvae by baculovirus recombinants.

Authors:  B E Johansson; P M Price; E D Kilbourne
Journal:  Vaccine       Date:  1995-06       Impact factor: 3.641

10.  Glycosylation of the viral attachment protein of avian coronavirus is essential for host cell and receptor binding.

Authors:  Lisa M Parsons; Kim M Bouwman; Hugo Azurmendi; Robert P de Vries; John F Cipollo; Monique H Verheije
Journal:  J Biol Chem       Date:  2019-03-22       Impact factor: 5.157

View more
  2 in total

1.  Pre-existing antibodies directed against a tetramerizing domain enhance the immune response against artificially stabilized soluble tetrameric influenza neuraminidase.

Authors:  João Paulo Portela Catani; Emma R Job; Tine Ysenbaert; Anouk Smet; Satyajit Ray; Lauren LaRue; Svetlana Stegalkina; Mario Barro; Thorsten U Vogel; Xavier Saelens
Journal:  NPJ Vaccines       Date:  2022-01-27       Impact factor: 7.344

Review 2.  Influenza Neuraminidase Characteristics and Potential as a Vaccine Target.

Authors:  Sarah Creytens; Mirte N Pascha; Marlies Ballegeer; Xavier Saelens; Cornelis A M de Haan
Journal:  Front Immunol       Date:  2021-11-16       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.